Healthcare's three gatekeepers just narrowed the door
Insurers are leaving ACA markets, FDA is closing the compounding loophole on GLP-1s, and AI proved diagnostic superiority in peer review while clinicians remain too burned out to use it.
enrollees losing Cigna ACA coverage by end of 2027
Cigna's exit follows enhanced subsidy expiration and comes after UnitedHealth and Aetna withdrew from similar markets in 2017-2018, concentrating individual market risk among fewer carriers.
One pattern. Trace it.
- 01
A pattern worth naming
(2) FDA compounding rule timeline — the proposed GLP-1 removal will have a comment period; watch for legal challenges from compounding pharmacies and patient advocacy pushback that could delay implementation. (3) CBER regulatory posture — Szarama's first substantive guidance documents or approval decisions will signal whether Prasad's approach intensifies or moderates.
- Shift
FDA moved to eliminate compounding eligibility for semaglutide, tirzepatide, and liraglutide, consolidating the GLP-1 market back to two manufacturers
- Shift
For the first time, peer-reviewed evidence in Science shows AI outperforming physicians on diagnostic reasoning in controlled settings
- Shift
No longer can health systems rely on compounded GLP-1 formulations to offer lower-cost weight management programs to patients
“If Cigna's 369,000 ACA enrollees land with our remaining competitors, do we have the network capacity to absorb overflow—or lose it?”
Ask your CFO to quantify revenue exposure from Cigna ACA patients and model the cost delta if your weight management program loses compounded GLP-1 access.
By Joseph Lancaster, Editor — with research from Pine Needle's intelligence layer.
The next argument lands tomorrow at 6 a.m. Pacific. Get it in your inbox →